ReviewCancer immunology, immunotherapy : CII2019
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy.
Review in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 68 citations in OpenAlex.
- A KRASMolecular therapy. Oncology · 2025Article
- Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers.Clinical and experimental medicine · 2025Review
- Dysregulated Sialylation in Cancer: From Immunosuppressive Microenvironment to Siglec-Targeted Therapeutics.Biomolecules · 2025Review
- In Vitro Evaluation of the Safety and Efficacy ofCancers · 2025Article
- Adopting tomorrow's therapies today: a perspective review of adoptive cell therapy in lung cancer.Therapeutic advances in medical oncology · 2025Review
- Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy.Journal for immunotherapy of cancer · 2024Review
- Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci.Nature communications · 2024Article
- The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Prognostic value of four immune-related genes in lower-grade gliomas: a biomarker discovery study.Frontiers in genetics · 2024Article
- An update on the biological characteristics and functions of tuft cells in the gut.Frontiers in cell and developmental biology · 2022Review
- The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors.Frontiers in immunology · 2022Review
- A novel risk score based on immune-related genes for hepatocellular carcinoma as a reliable prognostic biomarker and correlated with immune infiltration.Frontiers in immunology · 2022Article
- Review
- NOD2 deficiency confers a pro-tumorigenic macrophage phenotype to promote lung adenocarcinoma progression.Journal of cellular and molecular medicine · 2021Article
- The landscape of bispecific T cell engager in cancer treatment.Biomarker research · 2021Review
- A novel role for an old target: CD45 for breast cancer immunotherapy.Oncoimmunology · 2021Article
- MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion.Nature reviews. Immunology · 2021Review
- Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients.Scientific reports · 2021Article
- Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
Abstract
Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.